These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 8585764)

  • 21. PD0084430: a non-nucleoside inhibitor of human cytomegalovirus replication in vitro.
    Meyer AL; Bruening EE; Dunkle WE; Booth RJ; Steinbaugh BA; Vara Prasad JV
    Antiviral Res; 2001 Dec; 52(3):289-300. PubMed ID: 11675146
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitro.
    Mar EC; Cheng YC; Huang ES
    Antimicrob Agents Chemother; 1983 Oct; 24(4):518-21. PubMed ID: 6316844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and anti-HIV-1 activity of 2'-"up"-fluoro analogues of active anti-AIDS nucleosides 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxycytidine (DDC).
    Watanabe KA; Harada K; Zeidler J; Matulic-Adamic J; Takahashi K; Ren WY; Cheng LC; Fox JJ; Chou TC; Zhu QY
    J Med Chem; 1990 Aug; 33(8):2145-50. PubMed ID: 1695683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Valproic acid interferes with antiviral treatment in human cytomegalovirus-infected endothelial cells.
    Michaelis M; Ha TA; Doerr HW; Cinatl J
    Cardiovasc Res; 2008 Feb; 77(3):544-50. PubMed ID: 18006438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic significance and clinical impact of quantitative assays for diagnosis of human cytomegalovirus infection/disease in immunocompromised patients.
    Gerna G; Percivalle E; Baldanti F; Sarasini A; Zavattoni M; Furione M; Torsellini M; Revello MG
    New Microbiol; 1998 Jul; 21(3):293-308. PubMed ID: 9699213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synergistic effects by combination of ganciclovir and tricin on human cytomegalovirus replication in vitro.
    Yamada R; Suda H; Sadanari H; Matsubara K; Tuchida Y; Murayama T
    Antiviral Res; 2016 Jan; 125():79-83. PubMed ID: 26640224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alkoxy propane prodrugs of foscarnet: effect of alkyl chain length on in vitro antiviral activity in cells infected with HIV-1, HSV-1 and HCMV.
    Kini GD; Beadle JR; Xie H; Aldern KA; Richman DD; Hostetler KY
    Antiviral Res; 1997 Sep; 36(1):43-53. PubMed ID: 9330760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 2922).
    Mulamba GB; Hu A; Azad RF; Anderson KP; Coen DM
    Antimicrob Agents Chemother; 1998 Apr; 42(4):971-3. PubMed ID: 9559825
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New reporter cell line to evaluate the sequential emergence of multiple human cytomegalovirus mutations during in vitro drug exposure.
    Gilbert C; Boivin G
    Antimicrob Agents Chemother; 2005 Dec; 49(12):4860-6. PubMed ID: 16304146
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activity of different antiviral drug combinations against human cytomegalovirus replication in vitro.
    Snoeck R; Andrei G; Schols D; Balzarini J; De Clercq E
    Eur J Clin Microbiol Infect Dis; 1992 Dec; 11(12):1144-55. PubMed ID: 1337893
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potent and specific inhibition of HIV envelope-mediated cell fusion and virus binding by G quartet-forming oligonucleotide (ISIS 5320).
    Buckheit RW; Roberson JL; Lackman-Smith C; Wyatt JR; Vickers TA; Ecker DJ
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1497-506. PubMed ID: 7888204
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel chemical class of pUL97 protein kinase-specific inhibitors with strong anticytomegaloviral activity.
    Herget T; Freitag M; Morbitzer M; Kupfer R; Stamminger T; Marschall M
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4154-62. PubMed ID: 15504835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The antifungal drug isavuconazole inhibits the replication of human cytomegalovirus (HCMV) and acts synergistically with anti-HCMV drugs.
    Mercorelli B; Celegato M; Luganini A; Gribaudo G; Lepesheva GI; Loregian A
    Antiviral Res; 2021 May; 189():105062. PubMed ID: 33722615
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
    Tisdale M; Kemp SD; Parry NR; Larder BA
    Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis, in vitro anti-HIV and anti-hepatitis B activities and pharmacokinetic properties of amphiphilic heterodinucleoside phosphates containing ddC and AZT.
    Schwendener RA; Peghini PA; Ludwing PS; Schott H
    Nucleosides Nucleotides; 1999; 18(4-5):949-50. PubMed ID: 10432717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.
    Wagstaff AJ; Bryson HM
    Drugs; 1994 Aug; 48(2):199-226. PubMed ID: 7527325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-activity relationships of fluorinated nucleoside analogs and their synergistic effect in combination with phosphonoformate against human immunodeficiency virus type 1.
    Koshida R; Cox S; Harmenberg J; Gilljam G; Wahren B
    Antimicrob Agents Chemother; 1989 Dec; 33(12):2083-8. PubMed ID: 2533474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [In vitro susceptibility to ganciclovir and foscarnet of cytomegaloviruses].
    Otegui M; Rabella N; Labeaga R; Herrero M; Margall R; Muñoz JM; Prats G
    Rev Esp Quimioter; 2001 Jun; 14(2):155-64. PubMed ID: 11704769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between 3'-azido-3'-deoxythymidine resistance and primer unblocking activity in foscarnet-resistant mutants of human immunodeficiency virus type 1 reverse transcriptase.
    Meyer PR; Matsuura SE; Zonarich D; Chopra RR; Pendarvis E; Bazmi HZ; Mellors JW; Scott WA
    J Virol; 2003 Jun; 77(11):6127-37. PubMed ID: 12743270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased efficacy of ganciclovir in combination with foscarnet against cytomegalovirus and herpes simplex virus type 2 in vitro and in vivo.
    Freitas VR; Fraser-Smith EB; Matthews TR
    Antiviral Res; 1989 Nov; 12(4):205-12. PubMed ID: 2559657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.